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Background: Radioresistance is the common cause for radiotherapy failure in non-small cell lung cancer (NSCLC),
and the degree of radiosensitivity of tumor cells is different during different cell cycle phases. The objective of the
present study was to investigate the effects of cell cycle redistribution in the establishment of radioresistance in
NSCLC, as well as the signaling pathway of SH2 containing Tyrosine Phosphatase (SHP1).
Methods: A NSCLC subtype cell line, radioresistant A549 (A549S1), was induced by high-dose hypofractionated
ionizing radiations. Radiosensitivity-related parameters, cell cycle distribution and expression of cell cycle-related
proteins and SHP1 were investigated. siRNA was designed to down-regulate SHP1expression.
Results: Compared with native A549 cells, the proportion of cells in the S phase was increased, and cells in the
G0/G1 phase were consequently decreased, however, the proportion of cells in the G2/M phase did not change in
A549S1 cells. Moreover, the expression of SHP1, CDK4 and CylinD1 were significantly increased, while p16 was
significantly down-regulated in A549S1 cells compared with native A549 cells. Furthermore, inhibition of SHP1 by
siRNA increased the radiosensitivity of A549S1 cells, induced a G0/G1 phase arrest, down-regulated CDK4 and
CylinD1expressions, and up-regulated p16 expression.
Conclusions: SHP1 decreases the radiosensitivity of NSCLC cells through affecting cell cycle distribution. This
finding could unravel the molecular mechanism involved in NSCLC radioresistance.
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Lung cancer is one of the malignant tumors with the
fastest-growing morbidity and mortality in China. Non-
small cell lung cancer (NSCLC) accounts for 80-85% of
all lung cancer cases, and has a 5-year survival rate of
less than 15% [1]. Radiations therapy has been regarded
as the main treatment strategy for NSCLC for a long
time. However, radioresistance is the key issue limiting
the effects of radiations [2]. Due to the presence of tumor
cells heterogeneity, malignant cells might exhibit different
degrees of radiosensitivity even when they are from the
same histological differentiation status. Radioresistant cells
can survive to radiotherapy, which in turn induces the
local recurrence of NSCLC [3,4]. Many recent advances in
functional imaging and radiations therapy technology,* Correspondence: penggang1977@163.com
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reproduction in any medium, provided the orsuch as intensity-modulated radiation therapy (IMRT)
and image-guided radiation therapy (IGRT), allowed for
improved treatments. However, strategies for overcoming
the radioresistance-related treatment failure in NSCLC
are still largely unknown [5].
It has been found that the intrinsic radiosensitivity of cells
subpopulations present in low- and high-radiosensitive
subsets is different. This difference is based on the level of
hypoxia, DNA repair capacity, the number of dividing and
apoptotic cells and cell cycle phases. Among these, the
regulation of cell cycle might play a major role in this
process [6,7].
The biological behavior of NSCLC is closely related
to a variety of cellular signal transduction pathways
[8-12]. Protein tyrosine kinase (PTK) and protein tyrosine
phosphatase (PTP) are two important signals mediating
tyrosine phosphorylation and dephosphorylation, respect-
ively. PTK, PTP and their substrates act for signal trans-
duction. Previous studies have shown [13,14] that multiple. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the development of diseases. Indeed, the protein tyrosine
phosphatase SHP1 is a key regulator that mediates the level
of intracellular phosphorylation. The gene encoding this
protein is 17 kb long and contains 17 exons. The inter-
action of ligand and its receptor on the cell membrane can
induce the receptor dimerization after cytokines stimula-
tion. The receptor and its coupled JAK kinases can then be
activated via tyrosine phosphorylation. Meanwhile, the acti-
vated SH2 domain of SHP1 is able to catalyze JAKs or to
induce tyrosine dephosphorylation of other tyrosine kinases
(such as Src and c-fms). This induces a stop or a decrease
in the kinase activity, negatively regulates cellular signal
transduction, and inhibits cell proliferation [6,7,15-23].
Recent studies showed that SHP1 regulates cell cycle,
proliferation and tumor progression by modulating cell
cycle machinery through cyclin-dependent kinase 2
(CDK2), p27 and CyclinD1 [17]. In addition, the inhibition
of SHP1 in prostate cancer cells have been shown to induce
G0/G1 phase cell cycle arrest and to change some cell cycle
machinery, such as down-regulation of p27, CDK2 and
CDK6 [18]. Taken together, SHP1 is well-known to be
associated with cell cycle regulation.
We hypothesized that SHP1 might affect the radio-
sensitivity of NSCLC by modulating cell cycle. Thus,
SHP1 might serve as a potential target for regulating the
radioresistance of NSCLC. In this study, we first established
an A549 radioresistant subtype cell line (A549S1). We fur-
ther demonstrated the phenomenon of G0/G1 and S phase
arrest in this cell line, which was demonstrated by the data
showing an increase and a decrease in the proportion of
cells in the S and G0/G1 phase, respectively. Meanwhile,
we demonstrated that the cellular levels of SHP1, CDK4
and CylinD1 in this cell line were increased, while the level
of p16 was significantly decreased. Finally, the inhibition
of SHP1 expression in A549S1 cells up-regulated their
radiosensitivity and induced G0/G1 phase arrest. Taken
together, our results provide the molecular basis for
NSCLC radioresistance that can be leveraged in order to




The RPMI-1640 and G418 culture medium were purchased
from Gibco (GIBCO, Invitrogen Inc., Carlsbad, CA, USA).
Fetal bovine serum (FBS) was purchased from Hangzhou
Sijiqing Biological Engineering Materials Co., Ltd.
(Hangzhou, China). Trypsin, propidium (PI) and RNA
enzyme were from Sigma (St. Louis, MO, USA).
Lipofectamine 2000, Trizol, OPTI-MEM I and MMLV
reverse transcriptase were from Invitrogen (Carlsbad, CA,
USA). Taq DNA polymerase and Oligo dT primers
were from Invitrogen (Carlsbad, CA, USA). dNTPs andDNA/protein molecular weight standards were purchased
from Fermentas Inc. (Thermo Fisher Scientific, Waltham,
MA, USA). Protein lysis buffer and BCA protein assay
kit were from the Beyotime Institute of Biotechnology
(Wuhan, China). Protease inhibitors were from Roche
(Basel, Switzerland). Rabbit anti-human SHP-1, SHP-2,
p16, CDK4 and Cylin D1 monoclonal antibodies were
purchased from Cell Signaling Technology (Danvers, MA,
USA). The rabbit anti-human GAPDH antibody was from
Santa Cruz Biotechnologies Inc. (Santa Cruz, CA, USA).
HRP-conjugated goat anti-rabbit secondary antibody IgG
was purchased from Beijing Zhongshan Golden Bridge
Co., Ltd. (Beijing, China). The ECL chemiluminescence
reagent was from Pierce Chemicals (Rockford, IL, USA).
Cell culture
The human NSCLC cell line A549 was purchased from the
American Type Culture Collection (ATCC). Cells were cul-
tured in RPMI1640 medium containing 10% FBS, 100 IU
penicillin and 100 μg/mL streptomycin and incubated at
37°C and in a 5% CO2 humidified incubator.
Establishment of the NSCLC radioresistant subtype cell line
The A549S1 NSCLC radioresistant subtype cell line was
established as previously reported [24]. Briefly, 6 MV ioniz-
ing radiations from a Siemens Primus H high-energy linear
accelerator (Siemens, Erlangen, Germany) was used for
irradiation of A549 cells at a field of 10 × 10 cm and a
SSD of 100 cm, with an absorption dosage of 200 cGy/min.
A thick 1.5-cm block was used to cover culture bottles
for compensation. Parental A549 cells in the logarithmic
growth phase were randomly divided into two groups
(n = 3 per group). Each group received an irradiation
dose of 6 or 2 Gy/fraction, which was repeated for five or
fifteen fractions, respectively. After each fraction, the
cells were passaged at the end of the logarithmic growth
phase. Two cell clones were obtained from the surviving
cells, which were named A549S1 and A549S2, and were
used to investigate the radiosensitivity for three months
without irradiation.
The construction of PGCsiRNA
The SHP-1 transcript (NM_080549.3) was found on
the NCBI website and siRNA sequences were designed
according to the general international online design software
guidelines (www.ambion.com/techlib/misc/siRNAfinder.
html). siRNA sequences are listed in Table 1. pGCsiRNA-
NC was used as the negative control with 16 consecutive
bases that did not have any homology with the target
gene. pGCsiRNA1907, pGCsiRNA774 and pGCsiRNA-
NC (GenePharma, Shanghai, China) were transiently
transfected into the parental A549 cells using lipofectamine
2000. The interference efficiency was examined by RT-PCR
and Western blot 48 h after transfection.
Table 1 siRNA sequences for SHP1 gene
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Total RNA was extracted from the pGCsiRNA1907,
pGCsiRNA774 and pGCsiRNA-NC cell groups using
Trizol, according to the manufacturer’s instructions. RNA
purity was assessed by A260/A280. Total RNA (1 μg) was
reverse transcribed into cDNA using primer Oligo dT and
MMLV reverse transcriptase (Promega, CA, USA). Specific
mRNA quantification was performed by real-time PCR
using SYBR® Green master mixes (Life Technologies, NY,
USA) in ABI PRISM® 7900HT Sequence Detection System
(Life Technologies), according to the manufacturer’s
instructions. SHP-1 and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) primers were designed using
the Primer Premier 5.0 software. The gene-specific
primers used were: SHP-1 forward: 5′-AGA AGC AGG
AGT CCG AGG AT-3′, reverse: 5′- GCT GTG GTC AAA
GGG GAG AA -3′; GADPH forward: 5′- CTC CTC CTG
TTC GAC AGT CAG C -3′, reverse: 5′- CCC AAT ACG
ACC AAATCC GTT -3′. PCR reactions involved 45 cycles
of 95°C for 30 s, 60°C for 60 s. The Ct value was defined
as the number of PCR cycles in which the fluorescence
signal exceeded the detection threshold value. First, ΔCt =
Ct Gene - Ct GAPDH. Then, ΔΔCt = ΔCt treated - ΔCt
control. Lastly, 2-ΔΔCt was calculated to represent the
relative mRNA expression of target genes. GAPDH
was used as internal control.
Western blot
Cell lysates were prepared using the protein lysis buffer,
according to the manufacturer’s instructions. Following
extraction, protein concentration was determined by a
BCA assay. A total of 25 μg protein from each sample
was loaded into a 10% SDS-PAGE, followed by a transfer to
PVDF membrane (Millipore Corporation, Billerica, MA).
Membranes were blocked with 5% non-fat dry milk
overnight. They were then incubated with rabbit anti-
human SHP1, SHP2, p16, CDK4, GAPDH and CylinD1
antibodies at 4°C overnight. After washing, membranes
were incubated with horseradish peroxidase-conjugated
goat anti- rabbit IgG for 1 h. The ECL chromogenic agent
was used to develop the membranes and the optical density
of the bands was analyzed using the Image J software
(National Institutes of Health, Bethesda, MD, USA).Construction and identification of A549 cells stably
transfected plasmids
One day before transfection, A549S1 cells were trypsin-
digested and counted. Cells were plated in 6-well plates,
and the transfection was conducted when they reached
an 80-90% confluence. Cells were plated in 2 ml of DMEM
medium containing serum without antibiotics. A total of
2 μg pGCsiRNA1907 was diluted in 250 μl of OPTI-MEM
I medium, mixed gently and left at room temperature for
5 min. In the meantime, 5 μl of Lipofectamine 2000 was
diluted in 250 μl of OPTI-MEM I medium, mixed gently
and left at room temperature for 5 min. The diluted
pGCsiRNA1907 and Lipofectamine2000 (250 μl of each)
were gently mixed and left at room temperature for
20 min. The mixture was then transferred to the cell
culture plates, and mixed gently. After 24 h of culture in
a CO2 incubator at 37°C, cells were diluted, passaged
into three culture plates (10 cm diameter) and treated
with the G418 antibiotic (500 μg/ml) after 24 h. Empty
vector and blank controls without plasmid DNA were
used as negative controls.
Following two weeks of culture in DMEM medium
containing G418 (500 μg/ml) and 10% FBS, the formation
of monoclonal cell masses tranfected with target genes or
empty vector was observed. However, all cells without
plasmid DNA transfection died. Monoclonal cell masses
were digested with trypsin and transferred into 6-well
plates (2 ml DMEM mediun containing 500 μg/ml of G418
and 10% of FBS were added to each plate in advance).
Between 12 and 24 clone cell masses were picked up from
each transfection system. Cells were passaged into a T25
flask upon reaching an 80-90% confluence and collected
upon reaching a 100% confluence. Half of the cells were
used to extract RNA for RT-PCR analysis of the target gene
expression and the other half was used for cryopreserva-
tion. Cells with expression of the target gene were cultured
for three months using a compressing model and were sta-
bly transfected with the plasmid or empty vector; they were
named A549S1/siSHP1 and A549S1/siMock, respectively.
Clone formation assay for cell survival fraction analysis
A single cell suspension was prepared from the cells in
their logarithmic growth phase using 0.25% trypsin for
Table 2 Radiosensitivity parameters of different cell lines
Radiosensitivity parameters A549 A549S1 A549S2
SF2 0.60 0.83 0.67
D0 1.76 2.01 1.65
Dq 1.54 1.98 1.44
N 2.9 4.31 2.38
SF2: cell survival fraction in 2Gy irradiation dose; D0: mean lethal dose value;
Dq: quasithreshold dose; N: extrapolation number (N).
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a single-dose irradiation of 0, 2, 4, 6, 8 and 10 Gy after
a 12 h culture adherence. Two weeks later, cells were
treated with 4% paraformaldehyde and were stained using
Giemsa. Cell survival fraction (SF) was calculated based
on the following formula: SF = colony numbers in experi-
mental group/(Plating number × Plating efficiency (PE)).
PE = (colony numbers in control group/Plating effi-
ciency (PE)) × 100%. Cell survival curve was obtained
by the single-hit multi-target model (S = l-(1-e-D0/D)N)
using Sigma Plot 2001 Demo version. The parameters
of cell survival fraction, mean lethal dose value (D0),
quasithreshold dose (Dq) and extrapolation number
(N) were calculated with a 2 cGy irradiation dose (SF2).
Higher values of SF2, D0, Dq and N indicated a higher
radiosensitivity.
Cell cycle analysis by flow cytometry
A single cell suspension was made from cells in their
logarithmic growth phase using 0.25% trypsin for digestion.
Cells were placed in precooled 70% ethanol at −20°C for
fixation overnight. Cells were then washed in PBS and
digested using RNA enzyme. PI was added into the cells at
a final concentration of approximately 60 μg/ml. Cells were
incubated in the dark, and the cell cycle phases were exam-
ined by flow cytometry (Beckman, USA). All experiments
were conducted in triplicate.
Statistical analysis
Statistical analysis was performed using SPSS 17.0
(SPSS Inc., Chicago, IL, USA). Significant differences
between the groups were determined by the Student’s
t-test. A P-value <0.05 was considered to be statistically
significant (P < 0.05).Figure 1 Survival curves of A549, A549S1 and A549S2 cells.
Cell survival curves were obtained using the single-hit multi-target
model (S = l-(1-e-D0/D)N) and the parameters of cell survival fraction in
2Gy irradiation dose (SF2), mean lethal dose value (D0), quasithreshold
dose (Dq) and extrapolation number (N) were calculated.Results
Radiosensitivity changes in A549S1 and A549S2 cells
Clone formation assay was used to examine the sur-
vival fraction of A549, A549S1 and A549S2 cells fol-
lowing treatment with ionizing radiations. Results
showed that irradiation induced cell death in an expo-
nential manner (Figure 1). Table 2 shows the cellular
radiosensitivity parameters. SF2, D0, Dq and N were
increased in A549S1 cells. Moreover, the plateau phase
of the cell survival curve in A549S1 cells was also en-
hanced, suggesting a higher radioresistance in A549S1
cells compared with A549 cells. However, there were
no significant differences between A549S2 and A549
cells in terms of radiosensitivity parameters and of the
survival curves. These results suggest that high-dose
hypofractionated irradiation could induce the forma-
tion of radioresistant NSCLC cells, displaying a higher
radioresistance.
Radiosensitivity of A549 and A549S1 cell lines following a
three-month culture
After radioresistance establishment, A549S1 and A549S2
cells were cultured for three months, and survival fraction
was determined by the clone formation assay followed by
obtaining cell survival curve as shown in Figure 2. SF2,
D0, Dq and N radiosensitivity parameters are shown inFigure 2 Survival curves of A549, A549S1 and A549S2 cells
after three months of culture. Cell survival curves were obtained
using the single-hit multi-target model (S = l-(1-e-D0/D)N) and the
parameters of SF2, D0, Dq and N were calculated.
Table 3 Radiosensitivity parameters of different cell lines
after three months of culture
Radiosensitivity parameters A549 A549S1 A549S2
SF2 0.64 0.83 0.66
D0 1.45 2.11 1.43
Dq 1.55 2.37 1.65
N 2.31 4.32 2.43
SF2: cell survival fraction in 2Gy irradiation dose; D0: mean lethal dose value;
Dq: quasithreshold dose; N: extrapolation number (N).
Cao et al. Radiation Oncology 2013, 8:178 Page 5 of 9
http://www.ro-journal.com/content/8/1/178Table 3. Results showed that compared with A549 cells,
A549S1 cells maintained their radioresistant property
longer, even after a three-month culture.
Cell cycle changes in A549, A549S1 and A549S2 cell lines
Cell cycles of A549S1 and A549S2 following a three-month
culture are shown in Figure 3. The proportions of A549
cells in G0/G1, S and G2/M phase were 53.4 ± 0.8%,
22.0 ± 1.5% and 24.6 ± 1.5%, respectively. These proportions
were changed in A549S1 cells to 38.9 ± 1.9%, 42.0 ± 1.7%
and 19.1 ± 3.5%, respectively. When compared to A549
cells, the proportion of A549S1 cells in G0/G1 phase were
significantly decreased, while significantly increased for cells
in S phase (P <0.01). The proportion of A549S2 cells in
G0/G1, S and G2/M phase were 50.0 ± 3.1%, 30.4 ± 0.8%
and 19.8 ± 3.3%, respectively. There was no significant
differences when these proportions were compared to
those of A549 cells (P > 0.05).
SHP1, SHP2, p16, CDK4 and Cyclin D1 protein levels
changes in A549, A549S1 and A549S2 cells
As shown in Figure 4, expression levels of SHP1, CDK4
and CylinD1 were significantly increased, while p16 wasFigure 3 Assessment of cell cycle in A549, A549S1 and A549S2 cells.
A549S1 and A549S2 cells were detected by FACS analysis (**P < 0.01 vs. A5decreased in A549S1 cell when compared with A549 cell
(P < 0.05). There was no significant difference in SHP2
expression between A549S1 and A549 cells (P > 0.05).Efficiency of SHP1 siRNA in pGCsiRNA774 and pGCsiRNA1907
plasmids in A549S1 cells at mRNA and protein levels
As shown in Figure 5, both pGCsiRNA774 and
pGCsiRNA1907 plasmids containing SHP1 siRNA signifi-
cantly inhibited SHP1 mRNA and protein expression by
89.3 ± 5.0% and 92.9 ± 2.2%, respectively, when compared
with the control group (pGCsiRNA-NC).Effects of SHP1 siRNA on the expression of cell
cycle-related proteins
Positive clones for the pGCsiRNA1907 plasmid were
cultured for three months using a compressing model
in order to obtain a stably transfected A549S1 cell line
(A549S1/siSHP1). Cells transfected with empty vector were
regarded as A549S1/siMock. As shown in Figure 6, expres-
sion of SHP1, CDK4 and CylinD1 were down-regulated
by 56.7%, 62.1% and 47.1%, respectively. Furthermore,
p16 levels were increased by 3.39 folds in A549S1/
siSHP1 cells compared with A549S1/siMock cells.Stable SHP1 siRNA expression increased the
radiosensitivity of A549S1 cells
A549S1/siSHP1 cells were cultured for three months,
and their survival fraction was determined by the clone
formation assay along with cell survival curves, as shown
in Figure 7. SF2, D0, Dq and N radiosensitivity parameters
are listed in Table 4. Results showed that the radioresistance
of A549S1/siSHP1 cells was significantly decreased
compared with A549S1/siMock cells.Following culture for three months, cell cycle progression of A549,
49 cells).
Figure 4 Protein level changes in SHP1, SHP2, p16, CDK4 and Cyclin D1 in radioresistant cells. A549S1 and A549S2 cells were cultured for
three months. Cellular protein levels of SHP1, SHP2, p16, CDK4 and Cyclin D1 were examined by western blot. GAPDH was used as an internal
control (*P < 0.05; **P < 0.01 vs. A549 cells).
Figure 5 Assessment of SHP1-siRNA efficiency. (A) SHP1 mRNA expression in A549S1 cells was investigated by real-time RT-PCR following
transfection with pGCsiRNA774 and pGCsiRNA1907 plasmids. (B) SHP1 protein expression in A549S1 cells was investigated by western blot following
transfection with pGCsiRNA774 and pGCsiRNA1907 plasmids. GAPDH was used as an internal control (**P < 0.01 vs. the pGCsiRNA-NC group).
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Figure 6 Effects of stable SHP1 siRNA on the expression of cell
cycle-related proteins. Protein levels of SHP1, p16, CDK4 and
Cyclin D1 were examined in A549S1/siSHP1 and A549S1/siMock by
western blot. GAPDH was used as an internal control
(*P < 0.05, **P < 0.01 vs. the A549S1/siMOCK group).
Table 4 Radiosensitivity parameters of A549S1/siSHP1
and A549S1/siMock cells





SF2: cell survival fraction in 2 Gy irradiation dose; D0: mean lethal dose value;
Dq: quasithreshold dose; N: extrapolation number (N).
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As shown in Figure 8, the proportions of A549S1/siMock
cells in G0/G1, S and G2/M phase were 39.4 ± 3.5%,
47.9 ± 7.1% and 12.7 ± 1.5%, respectively. In A549S1/
siSHP1 cells, these proportions were changed to 63.3 ± 1.8%,
25.5 ± 2.8% and 11.3 ± 1.9%, respectively. These results
showed that the proportion of cells in G0/G1 phase was
significantly increased, while the proportion of cells in S
phase was significantly decreased in A549S1/siSHP1
cells compared with A549S1/siMock cells (P < 0.01). How-
ever, there was no significant difference in the proportion
of cells in G2/M phase between A549S1/siSHP1 and
A549S1/siMock (P > 0.05).
Discussion
It has been reported that a radioresistant phenotype in
cells can be changed to a radiosensitive one during
fractionated radiotherapy regimens, which could be
beneficial for increasing treatment efficiency in destroyingFigure 7 Survival curves of A549S1/siSHP1 and A549S1/siMock
cells. Survival curves were obtained using the single-hit multi-target
model (S = l-(1-e-D0/D)N) and the value of radiosensitivity
parameters SF2, D0, Dq and N were calculated.tumor cells. However, if the cell cycle does not change ac-
cordingly and effectively, this could lead to radioresistance.
Ionizing radiations can induce changes in cell cycle pro-
gression, such as G1 and G2 phases arrest. Moreover, the
arrest time is dependent on the intrinsic cell’s radiosensitiv-
ity, which is the key event for the cells to check the authen-
ticity and integrity of their genetic material, and to repair
damages. However, the detailed molecular mechanisms
for this process are still unknown [25]. In this study, we
investigated the relationship between radiosensitivity and
cell cycle in NSCLC, as well as its molecular mechanisms.
We successfully established a NSCLC radioresistant
cell line (A549S1 and S549S2) using two fractionated irradi-
ation methods. However, the best irradiation dose and frac-
tionation regimen for the generation of radiation-induced
resistance are still controversial. Previous studies demon-
strated that radioresistant subtype cell lines were rapidly
established by 3–5 fractions of 6 cGy [26]. Thus, in this
study, the A549S1 cell line was established by setting
the irradiation dose at 6 cGy/fraction for 5 fractions.
On the other hand, the control cell line A549S2 was
established by the general fractionated irradiation method
(2 cGy/fraction for 15 fractions). Results of this present
study showed that the radiosensitivity of A549S1 was
significantly decreased compared with A549 cells.
Previous studies have shown that there might be two
reasons for the formation of radioresistant cells, including
radiation-induced cell screening and cell mutation [26,27].
Indeed, radiosensitive cells are easily destroyed by ra-
diations, while radioresistant cells survive in the harsh
irradiated environment. In addition, radiations stimulate
structural changes at the cellular and molecular levels,
some of which induce a radioresistant phenotype by indu-
cing mutations. Cells radiosensitivity is different with differ-
ent cell cycle phases. For example, cells in S, G0/G1 and
G2/M phases are radioresistant, relatively radiosenstive and
radiosenstive, respectively [28].
Results from this study showed that the proportions
of cells in the S and G0/G1 phases were significantly
increased and decreased, respectively, in A549S1 cells
compared with A549 cells. The proportions of cells in
G2/M phase were not changed in these two cell lines,
suggesting an S phase arrest in A549S1 cells. Moreover, the
proportion of cells in each phase did not change in A549S2
Figure 8 Effects of stable SHP1 siRNA on cell cycle. Cell cycle progression of A549S1/siSHP1 and A549/siMock were examined by FACS
analysis (*P < 0.05, **P < 0.01 vs. A549S1/siMock).
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A549S1 was caused by changes in cell cycle progression.
Our data confirmed that high-dose hypofractionated
irradiation induced the formation of radioresistance in
cells in vitro, which was related to the cell cyle in the
tumor cells. These results are in line with previous
findings [25,28]. In the meantime, protein expression
levels of SHP1, CDK4 and CylinD1 were increased,
while p16 expression level was decrased in A549S1
cells, suggesting an important role of these factors in
radiosensitivity and cell cycle progression. Due to the
fact that SHP2 expression was not changed in A549S1
cells compared with A549 cells, we investigated the ef-
fect of SHP1 siRNA on the regulation of radiosensitiv-
ity, as well as on p16, Cyclin D1 and CDK4 expression.
SHP-1 is closely related to the regulation of cell cycle.
Indeed, a number of cellular proteins (such as protein
kinase C, SHP1, Rac, Rho and Scr) are activators of the
PI3K/Akt pathway, which has been demonstrated to play
a crucial role in cell cycle progression [17,18]. Activation
of the PI3K/Akt pathway increases Cyclin D1 and
CDK4, and decreases p16 [17,18]. Cyclin D1 is an im-
portant regulator in the transformation of G1 to S phase.
Normally, Cyclin D1 can bind with CDK4 to form a
complex promoting Rb phosphorylation and stimulating
cells transition from G1 into S phase. p16 is a tumor
suppressor gene, which causes G0/G1 phase cell arrest
by inhibiting Rb phosphorylation via p16 and Cyclin D1
competitory binding to CDK4. p16, Cyclin D1 and
CDK4 are cell cycle regulatory factors, and their gene
mutations or protein abnormalities are closely related to
tumorigenesis, tumor development and progression in a
variety of tumors [29]. However, even if these proteins
play a clear role in tumorigenesis, the exact relationship
between SHP1 and cell cycle-related proteins (Cyclin
D1, CDK4 and p16) and its function in NSCLC or
A549S1 cells is still unknown. Nevertheless, our results
show that SHP1 kncokdown using siRNA increases p16expression and decreases CDK4 and Cyclin D1 expres-
sions, which may be mediated by the PI3K/Akt pathway,
but how depletion of SHP1 results in an increase in p16
levels need to be further studied.
Our results showed that a stable SHP1 siRNA can in-
duce a higher radiosensitivity in A549S1 cells. Compared
with A549S1/siMock cells, the proportions of cells in S
and G0/G1 phases were significantly decreased and in-
creased in A549S1/siSHP1cells, respectively. Meanwhile,
the inhibition of SHP1 induced p16 up-regulation, and
CDK4 and CylinD1 down-regulation. These data sug-
gested that stable inhibition of SHP1 increased the ra-
diosensitivity by affecting the expression of CDK4,
CylinD1 and p16 (cell cycle related proteins), thus
delaying the G1/S checkpoint in NSCLC cells. Our re-
sults are supported by the recent observations indicating
that SHP1 supression induces G1/S arrest in prostate
cancer cells [18].
Conclusions
In summary, we observed that SHP-1 attenuated the ra-
diosensitivity of NSCLC cells through affecting cell cycle
induced by cell cycle-related proteins such as CDK4,
CylinD1 and p16. These findings could potentially in-
crease our understanding of the molecular mechanisms
involved in this process, and could identify potential tar-
gets to promote the efficacy of radiotherapy in NSCLC.
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